CIP2A and lip and oral cavity carcinoma: This formulation exhibited efficient therapeutic silencing of the CIP2A (Cellular Inhibitor of PP2A) oncogene in human tongue squamous cell carcinoma and reduced the invasiveness and anchorage-independent growth of oral cancer cells [88].